Ahcc10 Elegance Study

23/05/2024

Mirxes and the National Cancer Centre Singapore (NCCS) have developed a groundbreaking blood-based biomarker panel that can detect individuals at risk of developing liver cirrhosis, a major risk factor for liver cancer.

In a report by Lianhe Zaobao 联合早报, Professor Pierce Chow, Senior Consultant, Division of Surgery and Surgical Oncology at Singapore General Hospital and National Cancer Centre Singapore and Protocol Chair of ELEGANCE was quoted, "This new blood biomarker test has the potential to significantly improve liver cancer screening by offering a non-invasive and relatively low-cost method of identifying people at risk of liver cirrhosis, addressing a critical gap in early liver cancer detection. Once clinically validated, we are hopeful that this new biomarker panel will significantly improve patient outcomes."

本地生物科技公司觅瑞生物（MiRXES）与国立癌症中心联合开发了新的血液生物标志物检测（blood biomarker test）技术，为更多患者筛查肝硬化风险。新加坡中央医院与国...

15/01/2024

Last Thursday, we were pleased to hold the first ever Investigators' Meeting for AHCC10 ELEGANCE and AHCC11 PROSECT (Protocol Chair: Pierce Chow) since the studies' initiation during the COVID-19 pandemic.

With over 60 investigators and study team members in attendance, the meeting was a booming success as everyone was engaged in a productive discussion alongside a fruitful networking session. During the meeting, presentations on the progress of the programme and pilot study findings by our industry partners were made.

We would like to thank all our investigators and study members for your continuous support in ELEGANCE and commitment in developing better diagnostic tools and strategies for the early detection of liver cancer in Singapore. ❤️

11/12/2023

The Ahcc10 Elegance Study is still seeking patients with chronic liver disease to be part of our research to develop better diagnostic tools and strategies for early liver cancer detection. If you are interested to know more about the study, you may contact our study team members at +65 6326 6573 / ahcc10@nccs.com.sg to find out more.

24/10/2023

We are pleased to share with you the IMbrave050 article from Lancet (IF: 168.9) ahead of print, along with the press release by NCCS. Prof Pierce Chow is the senior author of this landmark randomized controlled trial which is the first in the world to demonstrate an effective adjuvant therapy for patients with HCC. This successful study reflects well on our network and the thought leadership of Singapore’s clinical and translational science.

In the NMRC OF-LCG PLANet programme, we are conducting the prospective AHCC12 EMPHASIS which is an adjuvant atezolizumab plus bevacizumab translational study in resected HCC patients that mirrors closely the positive IMbrave050. We aim to identify predictive biomarkers that can predict responders vs non-responders to the combination therapy, paving the way to precision medicine.

https://www.eurekalert.org/news-releases/1005549

https://doi.org/10.1016/S0140-6736(23)01796-8